Skip to main content

Anthrax may be the next tool in the fight against bladder cancer

Anthrax may soon help more people win the fight against bladder cancer, which the U.S. Centers for Disease Control and Prevention says strikes about 72,000 Americans each year and kills about 16,000, and is one of the most expensive cancers to treat.

The image features three scientific visuals, including an endoscopic view, an ultrasound image, and a microscopy image of a cellular structure.
Pet dogs suffering bladder cancer, for which all other approaches failed, were treated with a Purdue University experimental approach. A: Bladder cystoscopic biopsy being performed in patient dog to investigate tumor characteristics. B: Ultrasound image obtained to record tumor mass dimensions. Sagittal view of the bladder. Arrows point to mass in the neck of the bladder. C: Presence of Epidermal Growth Factor (EGF) Receptor on bladder cancer cells was revealed by binding and uptake of fluorescently labeled EGF (red). Nucleus (blue) and actin cytoskeleton (green) are also shown. (Image Provided)

The current treatments for bladder cancer are invasive for patients – who often must sit for hours at a time with a bladder full of an agent designed to kill cancer cells and tumors. Bladder cancer also is one of the most recurring for people diagnosed with the disease.

Now, researchers at Purdue University have come up with a way to combine the anthrax toxin with a growth factor to kill bladder cancer cells and tumors. The research is published in the Oct. 4 edition of the International Journal of Cancer.

R. Claudio Aguilar and his group worked with the Purdue teams led by Timothy Ratliff, a distinguished professor of comparative pathobiology and the Robert Wallace Miller Director of Purdue University Center for Cancer Research; and Deborah Knapp, the Dolores L. McCall Professor of Comparative Oncology and director of the Purdue Comparative Oncology Program, to test their solution in dogs with bladder cancer who had run out of other treatment options. They found this new agent decreased the tumor size without causing any other side effects in the animals.

Read the full story at Anthrax may be the next tool in the fight against bladder cancer

Recent Stories

“Paws Up” for Jennifer Danaher – brought to you by the PVM Wellness Committee

This week we express our gratitude to Jennifer Danaher, who is department secretary for Veterinary Clinical Sciences.

‘Purdue Pursuits’: A PVM angle on Purdue’s teaching and learning reading groups

Crafting meaningful and engaging course experiences has been at the top of Dielson Vieira’s mind ever since he joined the Purdue University College of Veterinary Medicine’s faculty in 2024. As a clinical assistant professor in the Department of Basic Medical Sciences, Vieira is already adept at applying innovative teaching practices to classroom environments, but that doesn’t stop him from seeking out new ideas, approaches and perspectives — insights he gains through outlets like Purdue’s teaching and learning reading groups.

Top tier biology journal publishes PVM study that unlocks secrets of a drug-resistant fungal pathogen, which causes serious infections in humans

Though the name “Candida auris” is far from a household term, public health experts know it well because the multi-drug-resistant fungal pathogen, which causes serious human infections, has been classified as an urgent threat by the U.S. Centers for Disease Control and Prevention (CDC) Antibiotic Threats Report (2019). Dr. Shankar Thangamani, Associate Professor of Microbiology and University Faculty Scholar in the Purdue University College of Veterinary Medicine’s Department of Comparative Pathobiology, is researching C. auris, aided by a 2.4 million grant from the National Institutes of Health (NIH). New research findings, just published in Nature Microbiology, show how C. auris adapts and evades the immune system.

In Print: ‘Translational Research Methods for Tauopathies’

A just-published 300-page volume edited by Jessica Fortin, Purdue assistant professor in the College of Veterinary Medicine’s Department of Basic Medical Sciences, provides a significant new resource for researchers studying a group of neurodegenerative diseases known as tauopathies. “Translational Research Methods for Tauopathies” provides detailed protocols intentionally selected to serve as a basis for research laboratories seeking to further treatments for such debilitating neurodegenerative diseases as Alzheimer’s and chronic traumatic encephalopathy (CTE).

It’s Almost Here!

Though the annual Purdue Veterinary Conference is almost upon us, there’s still time to register and take advantage of this time-honored College of Veterinary Medicine fall tradition that combines excellent continuing education with fun opportunities for reconnecting with colleagues and classmates, networking, and learning about the latest veterinary trends and products. The 2026 Purdue Veterinary Conference takes place September 23–26 on the Purdue University campus. The annual event has something for everyone, from veterinarians to veterinary technicians, faculty, staff and students.